GHRP-6 | Peptide Reference Material
RESEARCH PEPTIDE

GHRP-6 | Peptide Reference Material

Growth Hormone Secretagogue Hexapeptide — Research Peptide
$29.00
Synthetic GHS-R1a agonist hexapeptide supplied as a lyophilized laboratory reference material for receptor and endocrine-signaling studies. Research use only. Not for human or veterinary use.
✓ Scientific Identity Established
⏳ Laboratory Testing In Progress
⏳ Batch Documentation Pending
✓ Research Use Only
✓ U.S. Fulfillment
In Laboratory Testing
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
87616-84-0
Purity
≥98%
Molecular Formula
C46H56N12O6
Molecular Weight
873.0
Appearance
White lyophilized powder
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide growth-hormone secretagogue with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (D-tryptophan at position 2, D-phenylalanine at position 5, C-terminal amide). CAS 87616-84-0. It is supplied as a lyophilized peptide reference material for laboratory research use only.

As a research material, GHRP-6 is studied as an agonist of the growth-hormone-secretagogue receptor GHS-R1a (the ghrelin receptor). It is a distinct molecular entity from the selective secretagogue Ipamorelin and from endogenous ghrelin.

Primary Research Category
Growth Hormone Research
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Growth Hormone Axis Endocrine Research Receptor Pharmacology Receptor Binding

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

GHRP-6 is reported to act as an agonist at the growth-hormone-secretagogue receptor GHS-R1a (the ghrelin receptor), and in cell models GHRP-6 acting through this receptor regulates pituitary transcription factors such as Pit-1 (García et al., 2001). Separately, GHRP-6 has been reported to engage the scavenger receptor CD36 to mediate cardiovascular actions in the heart (Bodart et al., 2002). These are receptor- and cell-model characterizations; the GHS-R1a/ghrelin receptor is the exact governed molecular target, CD36 is reported but not in the governed vocabulary, and downstream growth-hormone/IGF-1 signaling is not asserted here as a direct molecular target.

Molecular Targets
  • Ghrelin Receptor (GHSR)
Primary Organ Systems
  • Endocrine System
  • Central Nervous System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

In Laboratory Testing
Laboratory Documentation In Progress

Laboratory documentation for the current lot is being completed.

Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Review Article•Methods in Enzymology• 2012

History to the Discovery of Ghrelin

Historical account by the originator of the growth-hormone-releasing peptides (including GHRP-6) tracing the development of GHRPs and the discovery of the ghrelin/GHS-R system.
Velora Research Insight
Founding/historical GHRP context from the GHRP originator (Bowers lineage). Cited as scientific/historical context, not a therapeutic or performance representation.
PubMed →DOI →
Mechanistic Study•Molecular Endocrinology• 2001

Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor

Mechanistic study reporting that ghrelin and GHRP-6, acting through the growth-hormone-secretagogue receptor (GHS-R1a), regulate expression of the pituitary transcription factor Pit-1.
Velora Research Insight
GHRP-6-specific GHS-R1a receptor-mechanism anchor (Diéguez/Smith lineage; Smith co-discovered the GHS-R). Establishes the governed GHSR target.
PubMed →DOI →
Mechanistic Study•Circulation Research• 2002

CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart

Mechanistic study reporting that the scavenger receptor CD36 mediates the cardiovascular action of growth-hormone-releasing peptides (including GHRP-6) in the heart, distinct from the GHS-R1a pathway.
Velora Research Insight
Independent second-receptor (CD36) cardiovascular-mechanism evidence (Ong/Montreal lineage). Basis for the reported CD36 vocabulary gap; not a target-vocabulary substitution.
PubMed →DOI →
Preclinical Study•Frontiers in Pharmacology• 2024

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damage

Preclinical study reporting that GHRP-6 prevented doxorubicin-induced myocardial and extra-myocardial damage in an animal model, characterizing a cytoprotective pharmacology.
Velora Research Insight
Independent GHRP-6-specific preclinical cytoprotection evidence (Berlanga-Acosta/CIGB lineage). Model-specific animal evidence, framed to its model and evidence level.
PubMed →DOI →